Compare Adaptive Biotechnologies Corp (ADPT) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Star Bulk Carriers Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Star Bulk Carriers Corp trades at $26.44 (market cap $2.92B). The key difference: Adaptive Biotechnologies Corp and Star Bulk Carriers Corp are close in size by market cap, and Star Bulk Carriers Corp pays a 3.93% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SBLK | |
|---|---|---|
Market Cap | $3.33B | $2.92B |
Sector | Health | Industrials |
52-Week High | $22.37 | $28.21 |
52-Week Low | $10.24 | $16.79 |
Enterprise Value | $3.19B | $3.62B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Star Bulk Carriers (SBLK) trades at $26.12, up 3.86% with bullish technical signals and strong earnings momentum after beating Q1 2026 estimates. The company shows solid fundamentals with 13.01% net income margin and positive cash flow, supported by a new dividend policy returning 100% of free cash flow. Analyst consensus is strongly bullish with 14 buy ratings.
SBLK presents a compelling investment case with earnings growth acceleration and shareholder-friendly capital allocation. Key risks include dry bulk market volatility and oil price sensitivity, but strong institutional support and technical momentum suggest continued upside potential for disciplined investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
